Equity Research · Tuesday, September 1, 2026
RDHL Stock Analysis for September 2026
Redhill Biopharma Ltd.
Price at Analysis
1Y Price Target
$0.45
-50.0%
vs current price
Technical Setup
RSI 53 / bearish (closed at day's low of $0.90 after opening at $1.36 — intraday distribution on massive volume) MACD
Support context: $0.57. Resistance context: $2.79.
Valuation Snapshot
P/E N/A (loss-making) / P/S N/A (Talicia divested; no meaningful trailing revenue base)
Market cap $4.02M; revenue Minimal post-Talicia divestiture.
Risk Watch
Nasdaq delisting
Non-compliance notification; failure to regain compliance forces OTC migration, destroying liquidity and financing access.
01 · Summary
Executive Summary
RedHill Biopharma is a distressed micro-cap biotech trading at $0.90 with a market cap of just $4.02M and only 23 employees. The company has received a Nasdaq non-compliance notification, recently divested its only commercialized product (Talicia) to Apotex for $18M upfront plus milestones, and continues to fund itself through dilutive private placements ($19.4M in June 2026 with heavy warrant overhang). The pipeline (opaganib, RHB-204, RHB-107) remains early-stage with no near-term revenue catalysts of high probability. The recent 139% intraday surge on the Talicia sale news and massive volume (103.9M shares) reflects speculative trading, not fundamental re-rating — the open of $1.36 collapsing back to $0.90 close shows the pop was sold into aggressively.
02 · Scenario Modeling
Price Targets
$0.45-50.0%
$0.15-83.3%
1-Year scenario price targets · Dashed line = current price
02 · Scenario Modeling
Scenario Analysis
| Scenario | 1Y Target | 1Y Growth | 3Y Target | 3Y Growth |
|---|---|---|---|---|
↑↑Hyper Bull | $6.00 | +566.7% | $15.00 | +1566.7% |
↑Bull | $2.20 | +144.4% | $4.50 | +400.0% |
→Neutral | $0.95 | +5.6% | $1.10 | +22.2% |
↓Bear | $0.45 | -50.0% | $0.15 | -83.3% |
↓↓Hyper Bear | $0.10 | -88.9% | $0.02 | -97.8% |
03 · Fundamentals
Key Financial Metrics
- Earnings Per Share (EPS)
- Negative
- Beta
- High (>2.0 estimated; extreme volatility on 103.9M share volume day)
- Revenue
- Minimal post-Talicia divestiture
- P/E Ratio
- N/A (loss-making)
- P/S Ratio
- N/A (Talicia divested; no meaningful trailing revenue base)
- Market Cap
- $4.02M
- Net Income
- Negative (persistent operating losses)
- Short Interest
- Elevated (typical for distressed micro-cap biotech; exact figure N/A)
- 52-Week Low
- $0.57
- 52-Week High
- $2.79
02 · Scenario Modeling
Technical Overview
Quant overlays derived from the existing 1Y OHLCV series: trend stack, sigma bands, regression fit, drawdown regime, and a composite signal model.
RSI (14)
53.3
Momentum Stack
1M +4.8% / 3M -33.9%
Volatility Regime
66.5% 20D vol
Regression Fit
+15.3% vs trend
Drawdown Curve
Distance from rolling peak, useful for regime stress and recovery speed.
-73.8%
Trend Regime
bearish
Price < 50D < 200D
Composite Signal
bearish
Bearish (-4)
Mean Reversion
bullish
+1.77 sigma
Breakout Status
neutral
Inside channel
Range Percentile
bearish
4th pct
Volume Impulse
bullish
1.58x 20D avg
Quant Dashboard
A compact read on trend persistence, stretch, realized risk, and breakout behavior.
- 1M Return
- +4.8%
- 6M Return
- -31.9%
- 1Y Return
- N/A
- ATR (14)
- $0.04
- 20D Vol
- 66.5%
- 60D Vol
- 87.0%
- Regression R²
- 0.70
- Price Z-Score
- +1.77
- 52W High
- $2.79
- 52W Low
- $0.57
- Range Position
- 4th pct
- Latest Volume
- 42.4K
04 · Research
Micro Analysis
RedHill has effectively sold its commercial future. Divesting Talicia — its only marketed product — for $18M upfront buys runway but strips the company of recurring revenue, converting it into a pure clinical-stage shell with a sub-scale pipeline. The Nasdaq compliance issue raises the specter of delisting, which would crush liquidity and institutional accessibility. The $11M Kukbo judgment enforcement is a potential one-time cash inflow but collection risk is real. The June private placement ($6M upfront, warrants for $13.4M more) signals continued dilution at depressed prices. Opaganib's rare pediatric disease designation for neuroblastoma is a modest positive (potential PRV), but neuroblastoma trials are years from approval at this scale of funding.
Talicia divestiture removes commercial base
Sale to Apotex for $18M upfront plus milestones (Aug 31, 2026) provides near-term cash but eliminates the company's only marketed product and its revenue stream. RedHill becomes entirely dependent on unproven clinical assets.
Nasdaq delisting risk
Nasdaq Staff Determination Notification for non-compliance. Delisting would move shares to OTC, severely impairing liquidity, institutional ownership, and financing access — a structural negative for a company that must raise capital.
Chronic dilution
June 2026 private placement: $6M upfront plus warrants for up to $13.4M more. With a $4M market cap, each raise is massively dilutive; warrant exercises create persistent overhang. Cash burn at 23 employees still exceeds internal generation post-Talicia.
Pipeline is early and underfunded
Opaganib (neuroblastoma, orphan/rare pediatric designations), RHB-204 (NTM/Crohn's), RHB-107 are all clinical-stage with no Phase 3 readouts near-term that the current balance sheet can credibly fund. NTM market CAGR of 12.6% is a real opportunity but RedHill lacks capital to capture it.
Kukbo judgment enforcement
$11M New York Supreme Court final judgment being enforced against Kukbo. If collected, it materially extends runway; if not, it's another broken promise. Cross-border enforcement is slow and uncertain.
04 · Research
Macro Analysis
Biotech funding conditions for sub-$50M micro-caps remain hostile: investors concentrate in late-stage assets, and small-cap biotech indices have lagged. Rising rate concerns in 2026 pressure speculative pre-revenue names hardest. GI/infectious disease markets are growing but competitive — Talicia faced entrenched H. pylori competitors, and NTM therapy space is attracting larger players. There is no macro tailwind that rescues a company at this size; survival depends on asset sales and licensing, not market conditions.
Hostile micro-cap biotech financing environment
Pre-revenue micro-caps face punitive financing terms; RedHill's June raise (heavy warrants at depressed prices) exemplifies this. Dilution spiral risk is the dominant macro-micro interaction.
Rate environment pressures speculative biotech
2026 rate-hike concerns have hit high-duration, cash-burning names. RDHL's -67.7% from 52-week high reflects this risk-off posture toward pre-commercial biotech.
Growing NTM and GI markets
NTM infections market projected at 12.6% CAGR (2026-2036) per DelveInsight — a genuine demand tailwind, but one RedHill can only monetize via partnership given its capital constraints.
Sector consolidation favors asset sellers
Larger pharma appetite for de-risked GI/oncology assets creates M&A or licensing optionality — the Talicia sale to Apotex shows this path is viable, though at modest valuations.
05 · Growth
Untapped Revenue Opportunities
Talicia sale proceeds and milestones
medium$18M upfront from Apotex plus undisclosed milestones funds operations near-term and validates the asset-sale strategy.
Kukbo judgment collection
medium$11M final judgment enforcement, if successful, would roughly triple the company's visible cash position relative to its market cap.
Opaganib partnering/PRV monetization
lowRare pediatric disease designation for neuroblastoma carries a potential Priority Review Voucher (sellable asset) plus out-licensing optionality for opaganib across oncology and inflammatory indications.
RHB-204 NTM/Crohn's licensing
lowNTM market growing at 12.6% CAGR; a partner could fund Phase 3 development in exchange for royalties, but data maturity is likely insufficient today.
06 · Catalysts
Headwinds & Tailwinds
↓ Headwinds
Nasdaq delisting
highNon-compliance notification; failure to regain compliance forces OTC migration, destroying liquidity and financing access.
Loss of commercial revenue
highTalicia divestiture eliminates the only marketed product; the company has no recurring revenue to fund the pipeline.
Dilution spiral
highSub-$5M market cap forces raises at distressed terms; June placement warrants add up to $13.4M of future share issuance overhang.
Pipeline execution risk
highOpaganib, RHB-204, RHB-107 are early-stage; clinical failure at any node could render the equity worthless.
Going-concern/going-concern-adjacent risk
medium23 employees and minimal cash relative to clinical costs; survival depends on judgment collection and milestone payments materializing on schedule.
↑ Tailwinds
Cash infusions from asset sales
medium$18M Talicia upfront plus potential Kukbo $11M collection could total ~$29M against a $4M market cap — a large cash-to-cap ratio if both land.
Regulatory designations
lowOpaganib holds Orphan Drug plus Rare Pediatric Disease designations (potential PRV), improving asset value for partnering.
Growing NTM market
low12.6% CAGR NTM market with RHB-204 positioned as a differentiated fixed-dose combination with better tolerability.
Speculative squeeze potential
lowRecent 139% intraday move on 103.9M shares shows the stock can spike violently on news; low float dynamics create episodic upside.
07 · TL;DR
Analysis Summary
- Ticker
- RDHL
- Company
- Redhill Biopharma Ltd.
- Analysis Date
- 2026-09-01
- Price at Analysis
- $0.90
- Rating
- Sell
- 1Y Price Target
- $0.45
- 3Y Price Target
- $0.15
- Market Cap
- $4.02M
- P/E Ratio
- N/A (loss-making)
This analysis was generated on 2026-09-01 when RDHL was trading at $0.90. The base-case 1-year price target is $0.45 (-50.0% implied return). Scenario range: $0.10 (hyper bear) to $6.00 (hyper bull).